Back to Search
Start Over
Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease
- Source :
- Liver international : official journal of the International Association for the Study of the Liver. 39(5)
- Publication Year :
- 2018
-
Abstract
- BACKGROUND & AIMS We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD). METHODS Thirty obese (mean age 40.7 ± 9.1 years, BMI 33.2 ± 3.6 kg/m2 , 90% male) adults with NAFLD defined as liver fat fraction (LFF) > 5% on magnetic resonance imaging without other causes of hepatic steatosis were randomized to a supervised programme of energy restriction plus moderate-intensity exercise to induce ≥ 5% weight loss (DE group, n = 15), or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks, followed by 26 weeks with only advice to prevent weight regain. RESULTS Diet and exercise and LI groups had significant (P
- Subjects :
- Agonist
Adult
Male
medicine.medical_specialty
medicine.drug_class
Gastroenterology
law.invention
Body Mass Index
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Weight loss
Non-alcoholic Fatty Liver Disease
Internal medicine
Weight Loss
medicine
Humans
Hypoglycemic Agents
Healthy Lifestyle
Obesity
Prospective Studies
Exercise
Singapore
Hepatology
Liraglutide
business.industry
Fatty liver
Middle Aged
medicine.disease
Discontinuation
Liver
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
Female
Steatosis
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 14783231
- Volume :
- 39
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Liver international : official journal of the International Association for the Study of the Liver
- Accession number :
- edsair.doi.dedup.....50c68dabb4d8e986c81231ad0736125f